Cynata Therapeutics Limited Stock Net Income
| CYYNF Stock | USD 0.22 0.07 46.67% |
As of the 8th of February, Cynata Therapeutics shows the Risk Adjusted Performance of 0.1439, standard deviation of 6.47, and Mean Deviation of 2.11. Cynata Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cynata Therapeutics variance and kurtosis to decide if Cynata Therapeutics is priced correctly, providing market reflects its regular price of 0.22 per share. As Cynata Therapeutics appears to be a penny stock we also recommend to validate its information ratio numbers.
Cynata Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cynata Therapeutics' valuation are provided below:Cynata Therapeutics Limited does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Cynata |
Cynata Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cynata Therapeutics' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cynata Therapeutics.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in Cynata Therapeutics on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding Cynata Therapeutics Limited or generate 0.0% return on investment in Cynata Therapeutics over 90 days. Cynata Therapeutics is related to or competes with Sernova Corp, Defence Therapeutics, Medical Developments, and Novacyt SA. Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem ... More
Cynata Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cynata Therapeutics' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cynata Therapeutics Limited upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1539 | |||
| Maximum Drawdown | 46.67 |
Cynata Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cynata Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cynata Therapeutics' standard deviation. In reality, there are many statistical measures that can use Cynata Therapeutics historical prices to predict the future Cynata Therapeutics' volatility.| Risk Adjusted Performance | 0.1439 | |||
| Jensen Alpha | 1.07 | |||
| Total Risk Alpha | 0.4357 | |||
| Treynor Ratio | 31.83 |
Cynata Therapeutics February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1439 | |||
| Market Risk Adjusted Performance | 31.84 | |||
| Mean Deviation | 2.11 | |||
| Coefficient Of Variation | 596.28 | |||
| Standard Deviation | 6.47 | |||
| Variance | 41.92 | |||
| Information Ratio | 0.1539 | |||
| Jensen Alpha | 1.07 | |||
| Total Risk Alpha | 0.4357 | |||
| Treynor Ratio | 31.83 | |||
| Maximum Drawdown | 46.67 | |||
| Skewness | 6.33 | |||
| Kurtosis | 41.44 |
Cynata Therapeutics Backtested Returns
Cynata Therapeutics is out of control given 3 months investment horizon. Cynata Therapeutics secures Sharpe Ratio (or Efficiency) of 0.17, which signifies that the company had a 0.17 % return per unit of risk over the last 3 months. We were able to interpolate nineteen different technical indicators, which can help you to evaluate if expected returns of 1.12% are justified by taking the suggested risk. Use Cynata Therapeutics Standard Deviation of 6.47, risk adjusted performance of 0.1439, and Mean Deviation of 2.11 to evaluate company specific risk that cannot be diversified away. Cynata Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.0338, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cynata Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cynata Therapeutics is expected to be smaller as well. Use Cynata Therapeutics variance, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to analyze future returns on Cynata Therapeutics.
Auto-correlation | 0.21 |
Weak predictability
Cynata Therapeutics Limited has weak predictability. Overlapping area represents the amount of predictability between Cynata Therapeutics time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cynata Therapeutics price movement. The serial correlation of 0.21 indicates that over 21.0% of current Cynata Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.21 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Cynata Therapeutics Limited reported net income of (5.45 Million). This is 101.6% lower than that of the Healthcare sector and 107.77% lower than that of the Biotechnology industry. The net income for all United States stocks is 100.95% higher than that of the company.
Cynata Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cynata Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Cynata Therapeutics could also be used in its relative valuation, which is a method of valuing Cynata Therapeutics by comparing valuation metrics of similar companies.Cynata Therapeutics is currently under evaluation in net income category among its peers.
Cynata Fundamentals
| Return On Equity | -0.21 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.70) % | |||
| Operating Margin | (0.78) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 143.28 M | |||
| Shares Owned By Insiders | 14.77 % | |||
| Shares Owned By Institutions | 24.80 % | |||
| Price To Book | 2.66 X | |||
| Price To Sales | 5.53 X | |||
| Revenue | 7.77 M | |||
| Gross Profit | 7.77 M | |||
| EBITDA | (13.56 M) | |||
| Net Income | (5.45 M) | |||
| Cash And Equivalents | 26.79 M | |||
| Cash Per Share | 0.19 X | |||
| Current Ratio | 16.25 X | |||
| Book Value Per Share | 0.17 X | |||
| Cash Flow From Operations | (3.3 M) | |||
| Earnings Per Share | (0.02) X | |||
| Number Of Employees | 10 | |||
| Beta | 0.61 | |||
| Market Capitalization | 35.82 M | |||
| Total Asset | 26.55 M | |||
| Net Asset | 26.55 M |
About Cynata Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cynata Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cynata Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cynata Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Cynata Pink Sheet
Cynata Therapeutics financial ratios help investors to determine whether Cynata Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cynata with respect to the benefits of owning Cynata Therapeutics security.